Form 8-K - Current report:
SEC Accession No. 0001493152-21-026636
Filing Date
2021-10-28
Accepted
2021-10-28 16:54:08
Documents
12
Period of Report
2021-10-26
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 34115
  Complete submission text file 0001493152-21-026636.txt   205241

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE anix-20211026.xsd EX-101.SCH 3015
3 XBRL LABEL FILE anix-20211026_lab.xml EX-101.LAB 34239
4 XBRL PRESENTATION FILE anix-20211026_pre.xml EX-101.PRE 22352
5 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3621
Mailing Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118
Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118 408-708-9808
Anixa Biosciences Inc (Filer) CIK: 0000715446 (see all company filings)

EIN.: 112622630 | State of Incorp.: DE | Fiscal Year End: 1031
Type: 8-K | Act: 34 | File No.: 001-37492 | Film No.: 211359154
SIC: 2834 Pharmaceutical Preparations